BNTX stock slips after cancer vaccine trial halt, BMO calls it clear setback
BNTX is on track for its worst day since March following a cancer vaccine trial halt, per TradingView News citing BMO Capital.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.